Veracyte (VCYT) is in focus after a busy period of clinical milestones, led by the U.S. commercial launch of its Prosigna Breast Risk of Recurrence test and new Phase III data across breast and prostate cancer.

Despite a small pullback in the latest session, with the 1 day share price return down 3%, Veracyte’s 30 day share price return of 16.95% and 90 day share price return of 44.2% sit alongside a 1 year total shareholder return of 69.73%. This suggests that recent clinical and product news is feeding into stronger momentum.

If precision oncology is on your radar after Veracyte’s news, it could be worth scanning a wider set of healthcare AI opportunities through the 39 healthcare AI stocks.

With Veracyte trading at US$47.27, sitting close to an average analyst target of US$49.10 and an indicated 18% intrinsic discount, investors now need to ask: is this a genuine value gap or is future growth already priced in?

Most Popular Narrative: 3.7% Undervalued

The most followed narrative pegs Veracyte’s fair value at $49.10, a touch above the last close of $47.27, and anchors that view in detailed growth and margin assumptions.

Pipeline momentum, with five major product launches and a pivotal clinical study (OPTIMA) completing in the next 18 months, positions Veracyte to further diversify revenue, drive cross-selling, penetrate new markets (e.g., MRD in bladder cancer, Prosigna for breast cancer), and significantly expand addressable markets, supporting long-term topline acceleration.

Curious what sits behind that fair value gap? The narrative leans heavily on steady revenue expansion, resilient profit margins, and a future earnings profile that assumes a premium multiple. The exact mix of growth rates, earnings power, and discount rate is spelled out there, and it is more ambitious than a simple back-of-the-envelope model.

Result: Fair Value of $49.10 (UNDERVALUED)

However, this depends on continued strength from Afirma and Decipher. It also assumes that new tests secure timely payer coverage and guideline inclusion, which may not occur.

Another Angle On Valuation

The earlier fair value view leans on analyst forecasts and a premium P/E above the broader US Biotechs industry. A contrasting take comes from the fair ratio, which suggests Veracyte’s current 42.9x P/E sits well above a 17.5x fair ratio and even a 41x peer average. That kind of gap can signal valuation risk as much as potential.

To unpack what that high P/E could mean for upside and downside, it helps to walk through the numbers in more detail. This is exactly what the valuation breakdown does, starting with the fair ratio as a reference point for where the market could eventually settle on this stock, See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

Given the mixed signals on valuation and growth expectations, this is a good moment to review the numbers yourself and consider acting before sentiment shifts. To see what investors are currently optimistic about, take a closer look at the 3 key rewards.

Looking for more investment ideas?

If Veracyte has caught your attention, do not stop here. Cast the net wider now so you are not catching up after the next big move.

• Spot potential value opportunities early by scanning the 47 high quality undervalued stocks that combine quality fundamentals with attractive pricing.
• Strengthen your core holdings by reviewing the solid balance sheet and fundamentals stocks screener (46 results) for companies with resilient financial foundations.
• Get ahead of the crowd by searching the screener containing 21 high quality undiscovered gems that most portfolios may be overlooking.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.